MedTrace Logo

Parasite-based Diagnosis for Malaria in Uganda: Feasibility and Cost-Effectiveness

NCT00565071 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 102087

Last updated 2012-03-28

No results posted yet for this study

Summary

The purpose of this study is to compare the cost-effectiveness of treating malaria based on three methods of diagnosis (rapid test, microscopy and presumptive diagnosis) among patients attending level three government health centres located in areas of low and high transmission intensities in Uganda. The study hypotheses are: in both low and high transmission areas, cost-effectiveness of malaria treatment with Artemether-Lumefantrine will be improved by the adoption of rapid diagnostic tests when compared with presumptive diagnosis or microscopy; and the difference between the cost-effectiveness of Artemether-Lumefantrine treatment following rapid diagnostic test or microscopy versus presumptive diagnosis will be greatest in low transmission areas.

Conditions

Interventions

DEVICE

Field microscopy and Paracheck Pf®

Malaria diagnosis based on microscopy and or Paracheck Pf®. Artemether/Lumefantrine (20mg/120mg) is first-line drug in all arms

Sponsors & Collaborators

  • Department for International Development, United Kingdom

    collaborator OTHER_GOV

  • Makerere University

    lead OTHER

Principal Investigators

  • Fred Nuwaha, MD, PhD · Department of Disease Control and Environmental Health, Makerere Universtiy School of Public Health

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
3 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2012-03-31
Completion
2012-12-31

Countries

  • Uganda

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00565071 on ClinicalTrials.gov